RT Journal Article
SR Electronic
T1 Increased prevalence and clinical impact of hypocalcaemia in severe COVID-19 distinguishes it from other forms of infective pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.27.21257813
DO 10.1101/2021.05.27.21257813
A1 Mehta, Meera R
A1 Ghani, Hakim
A1 Chua, Felix
A1 Draper, Adrian
A1 Calmonson, Sam
A1 Prabhakar, Meghna
A1 Shah, Rijul
A1 Navarra, Alessio
A1 Vaghela, Tejal
A1 Barlow, Andrew
A1 Vancheeswaran, Rama
YR 2021
UL http://medrxiv.org/content/early/2021/05/29/2021.05.27.21257813.abstract
AB Background Hypocalcaemia has been reported in the context of acute COVID-19, where it has been associated with an increased risk of hospitalisation and disease severity. Calcium is an important intracellular messenger that controls diverse cellular processes. Two other clinically important coronaviruses, SARS-CoV-1 and Middle East respiratory syndrome (MERS)-CoV, can use calcium ions to enter and replicate within host cells. Calcium may therefore be important in the pathophysiology of COVID-19 infection. We sought to investigate whether calcium derangement was a specific feature of COVID-19 that distinguishes it from other infective pneumonias, and its association with disease severity.Methods We conducted a single centre retrospective study of albumin-corrected serum calcium on adult patients with COVID-19 who presented between March 1st and May 16th 2020. The primary outcome was maximal level of care based on the World Health Organization Clinical Progression Scale for COVID-19. Cases with community acquired pneumonia (CAP) and viral pneumonia (VP) were identified through a clinical database over three intervals (January to February 2018, January to February 2019 and September to December 2019).Results We analysed data from 506 patients with COVID-19, 95 patients with CAP and 152 patients with VP. Hypocalcaemia (serum calcium <2.2mmol/L) was a specific and common clinical finding in patients with COVID-19 that was not present in other respiratory infections. Calcium levels were significantly lower in those with severe disease. Ordinal regression of risk estimates for categorised care levels showed that baseline hypocalcaemia was incrementally associated with odds ratio of 2.33 for higher level of care, superior to other variables that have previously been shown to predict worse COVID-19 outcome. Serial calcium levels showed improvement by day 7-9 of admission, only in in survivors of COVID-19.Conclusion Hypocalcaemia may independently predict not only more severe but more progressive disease and warrants detailed prognostic investigation. The fact that decreased serum calcium is observed at the time of clinical presentation in COVID-19, but not other infective pneumonias, suggests that its early derangement is pathophysiological and may influence the deleterious evolution of this disease. If calcium is ultimately shown to be critical to the entry and replication of SARS-CoV-2 in host cells, unravelling how this mechanism could be therapeutically targeted deserves more intensive examination.Trial registration HRA 20/HRA/2344.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialStudy part of PREDICT COVID UK. Ethical approval for PREDICT COVID UK is provided by Stanmore Research Ethics Committee, London, England (IRAS ID: 283888). The study is registered by the National Health Service Health Research Authority under the reference 20/HRA/2344.Funding StatementThis research received no specific grant from any funding agency in public, commercial or not for profit sectors Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Part of PREDICT COVID UK with ethical approval provided by Stanmore Research Ethics Committee, London, England (IRAS ID: 283888). The study is registered by the National Health Service Health Research Authority under the reference 20/HRA/2344.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. Deidentified participant data may be requested from the corresponding author following publication of the study.